Senate Democrats Revive Full Cannabis Legalization Bill

Photo by Ramaz Bluashvili via Pexels.

Cory Booker, Chuck Schumer, and Ron Wyden reintroduced the Cannabis Administration and Opportunity Act on July 16, 2026, bringing the total roster of Senate backers to 17. If that bill name sounds familiar, it should — this is the fourth time it's been dropped into the Senate hopper since 2021, which tells you something about where it sits in the party's strategy at this point. It's no longer a one-off press release timed to 4/20. It's become a recurring fixture, the kind of bill Democrats reintroduce each Congress the way some members reintroduce a statehood bill for D.C. or a court-packing proposal — less about passing it this term and more about keeping a marker planted in the ground.

The timing is what makes this round worth paying attention to. CAOA landed the day after a DEA administrative law judge wrapped hearings on a completely different reform path: moving cannabis from Schedule I to Schedule III under the Controlled Substances Act. That process has been grinding along for more than two years now, and it's nowhere near finished. So for a few weeks at least, Washington has two live cannabis reform tracks running in parallel — one legislative, one administrative — and they're not remotely aiming at the same target. Rescheduling to Schedule III is a meaningful but bounded shift. Full descheduling, which is what CAOA does, is a structurally different animal, and understanding the gap between the two is the key to reading everything else happening in cannabis policy this year.

What's Actually in the CAOA

Photo by Alesia Kozik via Pexels.

The core move in CAOA isn't reclassification — it's removal. The bill takes cannabis off the federal Controlled Substances Act entirely, which is a fundamentally different act than shifting it to a lower schedule. Under CAOA, the federal government would step back from treating cannabis as a controlled substance at all, leaving individual states free to legalize, regulate, or continue to prohibit it as they see fit, similar to how alcohol is handled after repeal. That's a much bigger swing than anything the DEA is currently contemplating.

Beyond descheduling, the bill carries a lot of the policy weight advocates have wanted bundled together for years. It includes federal expungement and resentencing provisions for people with prior cannabis convictions, aiming to unwind some of the collateral damage from decades of enforcement. It sets up a federal regulatory and taxation structure run through the Treasury's Alcohol and Tobacco Tax and Trade Bureau, paired with FDA-style labeling standards so products would carry consistent potency and ingredient information across state lines. There's also dedicated funding directed toward cannabis research, which researchers have complained for years is hard to get approved and funded given cannabis's legal status.

The bill also tries to address consequences that don't show up in headlines but matter enormously to real people: loss of federal benefits, housing instability tied to cannabis use or convictions, and immigration consequences for noncitizens. New worker protection language is in this version too, along with provisions aimed at the hemp-derived THC products currently facing a potential federal ban — an issue that's become its own flashpoint as gas station delta-8 and delta-9 products have proliferated in states with no adult-use programs. None of this is new territory for the bill; versions in 2021 and 2024 covered similar ground and never got a floor vote in either chamber.

The Senators Behind It

Photo by Laura Musikanski via Pexels.

Booker, Schumer, and Wyden are running this as a leadership play, not a backbench gesture. Schumer's presence as Majority Leader (well, former, depending on the chamber's makeup this cycle) still carries weight in signaling this is a caucus priority rather than one senator's pet project, and Booker has been the most consistent evangelist for full descheduling going back years before this bill even had a name.

Thirteen additional Democrats signed on as original cosponsors, bringing the total to 17 senators. The list includes John Hickenlooper and Michael Bennet of Colorado — a state with one of the oldest adult-use markets in the country — along with John Fetterman of Pennsylvania and Peter Welch of Vermont. It's a caucus-spanning group in terms of geography, but notably not in terms of party. Zero Republicans have signed on as cosponsors, and that absence is doing most of the work in explaining why nobody in Washington expects this bill to reach the floor this Congress, let alone get a vote.

Booker's office leaned hard on public opinion numbers in the rollout, pointing to polling showing 91% of Americans support legal cannabis in some form, whether medical or adult-use. That's not a fringe position anymore by any measure, and it's the argument Democrats keep returning to: broad public support, paired with a federal law that hasn't caught up. But polling numbers don't move Senate procedure. Without Republican buy-in, CAOA functions as a marker bill — a way to keep full descheduling in the conversation and put something concrete on record ahead of whatever comes out of the DEA's rescheduling process, rather than a serious bid for passage this session.

CAOA vs. the DEA's Schedule III Track

The proposed bill fully deschedules cannabis rather than merely reclassifying it, and would end federal-state conflicts, include expungement provisions, and require a congressional vote to take effect.

While Booker's team was finalizing CAOA's reintroduction, a separate and arguably more consequential process was wrapping up a few blocks away. The DEA's administrative hearing on moving cannabis to Schedule III concluded on July 15, with Chief Administrative Law Judge Derek Julius overseeing the proceedings. Post-hearing briefs from the parties involved are due August 17, capped at 50 pages each, after which Julius will issue a recommendation to the DEA Administrator. There's no fixed deadline after that point for a final decision — this could stretch on for months, and Acting Attorney General Todd Blanche's original rescheduling order from earlier this year still faces active legal challenges that could complicate or delay implementation regardless of what Julius recommends.

It's worth being precise about what Schedule III would and wouldn't do, because it gets conflated with full legalization constantly in casual conversation. Schedule III keeps cannabis a federally controlled substance — just a less restrictive one, in the same tier as ketamine or anabolic steroids. It wouldn't legalize adult-use sales anywhere they aren't already legal under state law, and it wouldn't resolve the core federal-state conflict that adult-use operators in states like Colorado, California, or Michigan currently live with.

CAOA is a different order of change entirely. It removes cannabis from the CSA altogether rather than just shifting its tier, which matters enormously for the practical issues the industry has been fighting over for years — banking access, interstate commerce, and the punishing IRC Section 280E tax provision that currently blocks cannabis businesses from deducting ordinary business expenses because they're trafficking a Schedule I or II substance. Schedule III would likely ease the 280E burden somewhat, but full descheduling under CAOA would resolve it and the banking question far more comprehensively.

Where State Law Stands Right Now

Photo by Erik Mclean via Pexels.

State law has moved well past where federal law sits, and it's not particularly close anymore. Medical cannabis programs now exist in some form in nearly every state, even in places that haven't touched adult-use legalization at all. Twenty-four states plus several U.S. territories currently regulate adult-use sales, meaning most Americans now live somewhere cannabis is legal in at least one form — medical, adult-use, or both. That's the crux of the argument advocates keep making to Congress: the federal ban isn't just unpopular, it's increasingly disconnected from how most of the country actually lives.

Morgan Fox of NORML put it plainly in comments following CAOA's reintroduction, arguing that continued federal prohibition looks increasingly out of step with public opinion, state law, and the scientific evidence that's accumulated over the past decade. That's a fair read of the landscape at this point — it's hard to find another area of federal law where the gap between federal statute and lived reality in a majority of states is this wide.

None of that changes the fact that state programs differ enormously from one another, and readers shouldn't assume rules in one legal state carry over to another. Possession limits, licensing requirements for cultivators and retailers, and whether home cultivation is even allowed all vary significantly by state, and some states with medical programs only still carry real criminal penalties for adult-use possession. Anyone trying to figure out what's actually legal where they live should check their specific state and local rules directly rather than assume legality elsewhere applies to them.

Strip away the press releases and the realistic path for CAOA this Congress is close to zero without Republican cosponsors, and there's no sign of that changing anytime soon. That's not a knock on the bill so much as an honest read of where Senate math currently sits. Its actual function is different from passage — it keeps full descheduling alive as the stated goal of Senate Democrats while the DEA works through a much narrower, much slower administrative process that wouldn't get the industry or advocates anywhere close to what CAOA promises even if it clears every hurdle.

That two of these tracks are running simultaneously, aiming at such different endpoints, says something about where the federal government actually stands on cannabis reform. Congress, or at least the Democratic caucus within it, is signaling it wants the whole structure gone — cannabis off the CSA, states left to run their own show. The executive branch, through the DEA process, is inching toward a narrower fix that keeps federal control intact but loosens it a notch. Those aren't two versions of the same reform. They're two different visions of how much change cannabis policy actually needs, and right now neither branch has the votes or the authority to force the other's hand.

Two dates are worth watching if you want to know whether either path is actually speeding up. The first is August 17, when post-hearing briefs are due in the Schedule III proceeding — Julius's eventual recommendation will shape how fast, or how slowly, that process moves toward the DEA Administrator's desk. The second is less a date than a headcount: any sign of a Republican senator signing onto CAOA as a cosponsor. Until one of those two things moves, expect this to stay exactly where it's been for the past several Congresses — a lot of motion, not much movement.